Heather A. Halem

TL;DR: Adropinregulated expression of hepatic lipogenic genes and adipose tissue peroxisome proliferator-activated receptor gamma, a major regulator of lipogenesis, may be a factor governing glucose and lipid homeostasis, which protects against hepatosteatosis and hyperinsulinemia associated with obesity.

TL;DR: It is demonstrated that distinct melanocortin peptide drugs can have widely different efficacies and side effects, and treatment with a highly-selective novel MC4R agonist resulted in transient decreases in food intake, with persistent weight loss over 8 weeks of treatment in a diet-induced obese nonhuman primate model.

TL;DR: Ghrelin and a synthetic ghrelin receptor agonist improve weight gain and lean body mass retention via effects involving orexigenic neuropeptides and antiinflammatory changes.

TL;DR: It is concluded that ghrelin treatment in uremia results in improved lean mass accrual in part due to suppressed muscle proteolysis and possibly related to antiinflammatory effects.

TL;DR: Data speak against a sustained decrease in food intake, body fat, or body weight gain following PYY3‐36 administration and make the previously suggested role of the hypothalamic melanocortin system unlikely as is the existence of PYY deficiency in human obesity.